Innoviva (INVA) Accounts Payables (2010 - 2026)
Innoviva's (INVA) quarterly Accounts Payables came in at $6.5 million in Q1 2026, up 38.68% YoY from $4.7 million in Q1 2025, and up 31.25% on a QoQ basis from $5.0 million in Q4 2025.
Innoviva (INVA) Accounts Payables (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Accounts Payables data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Accounts Payables rose 38.68% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 38.68% YoY) and the FY2025 annual result came in at $5.0 million, up 132.93% from the prior year.
- Accounts Payables grew to $6.5 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.7 million in Q4 2023 to a low of $890000.0 in Q1 2024.
- A 5-year average of $4.2 million and a median of $4.3 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 14310.0% — and 2024, when it plunged 85.0%.
- Tracing INVA's Accounts Payables over 5 years: stood at $2.9 million in 2022, then surged by 128.55% to $6.7 million in 2023, then sank by 68.26% to $2.1 million in 2024, then soared by 132.93% to $5.0 million in 2025, then soared by 31.25% to $6.5 million in 2026.
- The last three Accounts Payables figures came in at $6.5 million (Q1 2026), $5.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Mar 31, 2026 | 6.52 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 5.38 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 890,000.00 |
| Dec 31, 2023 | 6.72 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 1.81 Mn |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 89,000.00 |